Diamond Therapeutics Announces First Patient Dosed in Health Canada Approved Trial Evaluating Low-Dose Psilocybin

World’s first systematic, pharmacokinetic/pharmacodynamic study of non-psychedelic doses of psilocybin.

Topic Anxiety Depression
Compound Psilocybin
Visit article
Category Press Release
Country Canada

Companies Featured

Diamond Therapeutics
We're creating safe, FDA, EMA and Health Canada supported treatments for neuropsychiatric conditions

?>